Financials data is unavailable for this security.
View more
Year on year Santen Pharmaceutical Co Ltd grew revenues 8.22% from 279.04bn to 301.97bn while net income improved from a loss of 14.95bn to a gain of 26.64bn.
| Gross margin | 57.92% |
|---|---|
| Net profit margin | 8.64% |
| Operating margin | 12.33% |
| Return on assets | 6.25% |
|---|---|
| Return on equity | 8.76% |
| Return on investment | 7.77% |
More ▼
Cash flow in JPYView more
In 2024, Santen Pharmaceutical Co Ltd increased its cash reserves by 63.35%, or 36.68bn. The company earned 72.65bn from its operations for a Cash Flow Margin of 24.06%. In addition the company used 6.15bn on investing activities and also paid 34.03bn in financing cash flows.
| Cash flow per share | 124.22 |
|---|---|
| Price/Cash flow per share | 13.66 |
| Book value per share | 827.65 |
|---|---|
| Tangible book value per share | 600.21 |
More ▼
Balance sheet in JPYView more
| Current ratio | 2.61 |
|---|---|
| Quick ratio | 1.97 |
| Total debt/total equity | 0.1955 |
|---|---|
| Total debt/total capital | 0.1639 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 3.13% and 287.48%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.09% |
|---|---|
| Div growth rate (5 year) | 4.88% |
| Payout ratio (TTM) | 46.36% |
| EPS growth(5 years) | -1.60 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 3.79 |
More ▼
